About Alaaeldin A Hamza
Dr. Alaaeldin Ahmed Hamza, who earned his PhD from Cairo University in animal physiology, is currently working as a professor of physiology at the National Organization for Drug Control and Research (NODCAR) in Egypt. He is an established scientist in the areas of liver toxicity, reproductive toxicity, and liver cancer. For his highly cited publications, he has been ranked among the top scientists in United Arab Emirates institutions according to GSC public profiles since 2017–2023 and among the top 2% of and between the top 2% of the world's scientists by Stanford University since 2020–2023. He has published more than 50 papers in different fields of pharmacology and toxicology in many prestigious journals such as Hepatology, Biomedicine & Pharmacotherapy, Frontiers in Pharmacology Scientific Report, Toxicology Letters, Toxicology, Food and Chemical Toxicology, Antioxidants, Andrologia, Life Sciences, and Molecules. His current Scopus H-index is 29 and his total citations are 3008. He serves as a reviewer in Elsevier, Taylor, Springer, and Wiley journals. He has served as an editorial board member of more than fifty international journals and also as an assistant editor in Frontiers of Experimental Pharmacology and Drug Discovery. He was recognized as one of the best reviewers in Elsevier (2011& 2017). He has participated in various national and international conferences. He has awarded the Best Individual Non-Funded Research Project Award, the 9th Annual Research Conference, U.A.E. University, Al-Ain. April 21–23, 2008. He was recognized as one of the best reviewers in Elsevier (2011& 2017). He is a member of the National Committee for Biological Science. Egyptian Academy of Scientific Research and Technology. 22-10-2018-2022. He is a member of the Medical Research Council, specialized scientific councils, and the National Committee for Biochemistry and Molecular Biology of the Egyptian Academy of Scientific Research and Technology since 2022. His research focus areas are the development of animal models to study the protective effects of natural substances and the antioxidant and oxidative stress induced by pharmacological agents such as anticancer drugs and pharmacological agents. For the last 10 years, he has been involved in developing in vivo and enzyme assays in the field of cancer and oxidative stress research. His experience has involved drug discovery, mechanism-of-action studies, biomarker development, cancer pharmacology in cancer cells and chemical tumor models, and the pharmacology of stress response signaling. This has required a broad understanding of cancer biology and pharmacology.